Skip Navigation LinksHome > January 2014 - Volume 62 - Issue 1 > Half-Dose Recombinant Tissue Plasminogen Activator Treatment...
Journal of Investigative Medicine:
doi: 10.231/JIM.0000000000000014
Original Articles

Half-Dose Recombinant Tissue Plasminogen Activator Treatment in Venous Thromboembolism

Canan Hasanoğlu, H. MD*; Hezer, Habibe MD; Karalezli, Ayşegül MD; Argüder, Emine MD; Kiliç, Hatice MD; Şentürk, Ayşegül MD; Er, Mükremin MD; Soytürk, Ayşe Nur MD

Collapse Box

Abstract

Introduction

Pulmonary embolism (VTE) comes in different degrees of severity from massive pulmonary embolism to nonmassive pulmonary embolism with no symptoms or hypoxia. Thrombolytic therapy is a lifesaver especially for patients who are in the high-risk group. In this study, we aimed at evaluating symptoms and clinical and laboratory findings in patients who had a diagnosis of massive or submassive VTE and treated with 50-mg recombinant tissue plasminogen activator (rt-PA) per hour for various problems as opposed to the standard dose, which is 100 mg every 2 hours.

Materials and Methods

Forty-six patients with a diagnosis of massive or submassive VTE who received thrombolytic therapy were evaluated retrospectively. Twenty-three patients who were treated with 50-mg rt-PA per hour were included in the study group. On the other hand, 23 patients who were treated with 100 mg of intravenous infusion of rt-PA every 2 hours were included in the control group. Echocardiographic assessment of the right ventricular size, systolic pulmonary artery pressure (sPAP), oxygen saturation, systemic arterial pressure, and heart rate before the thrombolytic therapy and in the first 24 hours after the administration of therapy were checked and noted in both of the groups.

Results

No significant difference was found between the 2 groups with regard to demographic data, Wells scores, type of embolism, average symptom duration, sPAP, and oxygen saturation. Differences in recovery, as inferred from vital symptoms and sPAP measurements, were not significant between the 2 groups.

Conclusions

Lower-dose thrombolytic therapy showed similar efficacy versus the standard dose in VTE. Thrombolytic therapy is a life-saving treatment in massive VTE. Furthermore, a harm/benefit analysis may lead to the administration of half-dose therapy in selected cases when it is contraindicated for various reasons.

Copyright © 2013 by The American Federation for Medical Research

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.